common glp 1 agonists GLP-1 Receptor as Treatments for Type 2 Diabetes nadis glp-1 GLP-1 receptor agonists
Description
Therefore, we analysed the population that discontinued treatment because of adverse reactions, rather than the overall discontinued population
Head-to-head trials comparing different GLP-1 agonists and the newer dual/triple agonists are needed to provide clarity for clinical decision making [92]
The remaining authors have no other disclosures
Moreover, the influence of pharmacogenetic polymorphisms, metabolic phenotypes, and sex differences remains incompletely understood
doi: 10.1016/j.pneurobio.2010.07.003
[DOI] [PubMed] [Google Scholar] 33.McGonagle D, Hermann KG, Tan AL
